borneol / Casp3 Cancer Research Results

BNL, borneol: Click to Expand ⟱
Features:
Borneol is a bicyclic organic compound and a type of monoterpenoid that occurs naturally in various essential oils.
-Recent studies have been exploring borneol’s ability to enhance drug delivery—especially across the blood-brain barrier.
-Borneol is particularly known for its ability to act as a penetration enhancer. This quality can improve the absorption of various drugs, potentially increasing their efficacy when used in combination with other therapeutic agents.
-Borneol is thought to temporarily open tight junctions between endothelial cells, enhancing drug penetration. It may also downregulate efflux transporters such as P-glycoprotein (P-gp), allowing higher intracellular concentrations of co-administered drugs.

Sources:
-Cinnamomum camphora (camphor tree), its essential oil contains borneol along with camphor.
-Dryobalanops aromatica,Often referred to as the camphor tree in Southeast Asia, its oleoresin is a well-known source of natural borneol.
-Blumea balsamifera

-The introduction of borneol led to a significant reduction in the size of selenium nanoparticles (SeNPs), as documented in the study (Prabhakaret et al., 2013)
-widely used as a messenger drug
-Borneol is always used as an adjuvant in combination with other drugs to reduce the dosage of other drugs, increase their therapeutic effect, and decrease drug side effects

Borneol — borneol is a bicyclic monoterpenoid alcohol present in several essential oils and also prepared synthetically; in biomedical use it functions less as a stand-alone anticancer drug than as a permeability enhancer, chemosensitizer, and CNS/brain-delivery adjuvant. It is best classified as a small-molecule natural product / terpene excipient-adjunct with pharmacologic activity. Standard abbreviations include BOR, BNL, and NB (natural borneol). Nestronics identifies the product as “born / borneol,” and the site notes its traditional sourcing from plants such as Cinnamomum camphora, Dryobalanops aromatica, and Blumea balsamifera. Across the current literature, borneol’s strongest translational niche is barrier modulation and drug co-delivery, especially toward the brain, while direct anticancer evidence remains preclinical.

Primary mechanisms (ranked):

  1. Barrier-permeation enhancement via reversible modulation of tight junction architecture and membrane permeability, especially at the BBB/BTB and other biological barriers.
  2. Efflux inhibition / chemosensitization, including suppression of P-glycoprotein and related ABC-transporter activity in barrier and tumor-associated contexts.
  3. Adjunct pro-apoptotic sensitization in cancer cells, often by amplifying ROS-linked oxidative injury and downstream caspase activation when combined with cytotoxics.
  4. Growth-signal suppression in some models, including interference with PI3K/AKT, MAPK balance, JAK1/STAT3, and hypoxia-linked HIF-1α signaling.
  5. Mitochondrial dysfunction as a downstream amplifier of drug-induced apoptosis in glioma and other preclinical models.
  6. Delivery-platform leverage in nanocarriers and CNS-targeted formulations, where borneol can improve tissue penetration more than intrinsic anticancer potency.

Bioavailability / PK relevance: Borneol is lipophilic, poorly water-soluble, and rapidly brain-penetrant, but oral administration showed the lowest absolute bioavailability among tested routes in mouse PK studies. Its main formulation value is therefore often as a permeation enhancer or co-formulation component rather than as a dependable high-exposure oral monotherapy. Intranasal, topical, trans-barrier, and carrier-based delivery have been investigated to exploit its barrier-opening properties.Nasal spray has been studied

In-vitro vs systemic exposure relevance: Common in-vitro anticancer studies use roughly 10–80 μM borneol. Those concentrations are not obviously impossible relative to high-dose animal brain exposures, but they are often achieved in preclinical settings using aggressive dosing and do not establish practical or safe systemic anticancer exposure in humans. For borneol, the more reproducible translational effect is usually concentration-assisted delivery enhancement of a partner drug rather than robust single-agent cytotoxicity. .

Clinical evidence status: Direct anticancer evidence is preclinical only. Human clinical evidence exists for non-cancer uses, including topical analgesia and borneol-containing cardiovascular/CNS formulations, but there is no established oncology approval or mature randomized cancer trial program supporting borneol as a stand-alone anticancer therapy.

Mechanistic table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Barrier permeability and tight junction modulation Drug entry ↑ Barrier permeability ↑ (reversible) R-G Improves penetration of co-administered agents Core translational mechanism. Reversible disassembly / redistribution of tight-junction proteins such as occludin and claudin-related architecture is central to borneol’s BBB/BTB and other barrier effects.
2 P-gp and ABC efflux suppression Drug retention ↑ resistance ↓ Protective efflux ↓ R-G Chemosensitization and enhanced CNS delivery Supported most strongly in BBB and transporter models; likely one reason borneol improves intracellular exposure to partner drugs. This is more convincing than a broad stand-alone tumoricidal claim.
3 ROS amplification with partner cytotoxics ROS ↑ ↔ (context-dependent) R-G Promotes oxidative damage and apoptosis In glioma combination studies, borneol enhanced cisplatin- or temozolomide-related killing through ROS overproduction, DNA-damage signaling, and apoptotic execution. This appears highly model- and combination-dependent.
4 Mitochondria and caspase apoptosis axis Mito dysfunction ↑ apoptosis ↑ ↔ G Facilitates mitochondrial apoptotic signaling Most evident in glioma chemosensitization literature, where borneol helps convert drug stress into mitochondrial injury and caspase activation.
5 PI3K/AKT and MAPK stress signaling AKT ↓ MAPK stress ↑ ↔ G Shifts survival signaling toward apoptosis Observed mainly in combination settings. Best interpreted as a downstream signaling consequence of oxidative/drug stress rather than the primary initiating event.
6 HIF-1α hypoxia adaptation HIF-1α ↓ ↔ G May reduce glioma survival under hypoxia A glioma-focused preclinical line suggests borneol can suppress HIF-1α-linked survival signaling, including via mTORC1/eIF4E-related regulation and autophagic degradation in newer work.
7 JAK1 and STAT3 signaling JAK1/STAT3 ↓ apoptosis ↑ ↔ G Suppresses proliferative and anti-apoptotic transcription Supported by a recent prostate cancer cell study. Promising but still narrow, preclinical, and not yet a validated pan-cancer borneol mechanism.
8 Selectivity and delivery-platform leverage Drug accumulation at target ↑ Off-target exposure risk ↑ (context-dependent) G Useful as adjunct in nanocarriers and brain-directed therapy Important industry-facing mechanism: borneol is often more valuable as a formulation adjuvant than as a primary cytotoxic agent.
9 Clinical Translation Constraint Single-agent potency uncertain CNS and barrier effects can be bidirectional G Limits direct oncology translation Key constraints are poor water solubility, lower oral bioavailability, route dependence, sparse human oncology data, stereochemical heterogeneity, and the possibility that barrier opening / efflux reduction may also alter normal-tissue exposure.

TSF legend

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
5653- BNL,    Borneol hinders the proliferation and induces apoptosis through the suppression of reactive oxygen species-mediated JAK1 and STAT-3 signaling in human prostate cancer cells
- in-vitro, Pca, PC3
ROS↑, TumCP↓, cycD1/CCND1↓, cycE1↓, Apoptosis↑, BAX↓, Casp3↑, Bcl-2↓, IL6↓, JAK1↓, STAT3↓,
5652- BNL,    Borneol promotes apoptosis of Human Glioma Cells through regulating HIF-1a expression via mTORC1/eIF4E pathway
- vitro+vivo, GBM, NA
Hif1a↓, Apoptosis↑, mTORC1↓, EIF4E↓, Bcl-2↓, BAX↑, Casp3↑, ChemoSen↑, ROS↑,
5651- BNL,  Cisplatin,    Natural borneol sensitizes human glioma cells to cisplatin-induced apoptosis by triggering ROS-mediated oxidative damage and regulation of MAPKs and PI3K/AKT pathway
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG
ChemoSen↑, tumCV↓, TumCCA↑, Apoptosis↑, ROS↑, DNAdam↑, ATR↑, ATM↑, P53↑, Histones↑, eff↓, Casp3↑, Casp7↑, Casp9↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 3,  

Core Metabolism/Glycolysis ⓘ

Histones↑, 1,  

Cell Death ⓘ

Apoptosis↑, 3,   BAX↓, 1,   BAX↑, 1,   Bcl-2↓, 2,   Casp3↑, 3,   Casp7↑, 1,   Casp9↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

DNA Damage & Repair ⓘ

ATM↑, 1,   ATR↑, 1,   DNAdam↑, 1,   P53↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   cycE1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EIF4E↓, 1,   mTORC1↓, 1,   STAT3↓, 1,  

Migration ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL6↓, 1,   JAK1↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,   eff↓, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  
Total Targets: 27

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
3 borneol
1 Cisplatin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:301  Target#:42  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page